FDA approves onabotulinumtoxinA to prevent chronic migraine

News
Article

FDA has approved onabotulinumtoxinA (Botox, Allergan Inc.) injection to prevent headaches in adult patients with chronic migraine.

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!
Recent Videos
Related Content
Survey: Part B Price Negotiation Could have Significant Impact on Providers

Survey: Part B Price Negotiation Could have Significant Impact on Providers

Denise Myshko
September 16th 2025
Article

Read More

Intercept Withdraws Ocaliva from Market After FDA Raises Safety Concerns

Intercept Withdraws Ocaliva from Market After FDA Raises Safety Concerns

Denise Myshko
September 16th 2025
Article

Read More

Big Beautiful Bill Reduces Drugs Eligible for Price Negotiations

Big Beautiful Bill Reduces Drugs Eligible for Price Negotiations

Denise Myshko
September 16th 2025
Article

Read More

ICER Finds GLP-1 Drugs Cost-Effective but Warns of Major Budget Strain

ICER Finds GLP-1 Drugs Cost-Effective but Warns of Major Budget Strain

Denise Myshko
September 16th 2025
Article

Read More

Nomad_Soul-stock@adobe.com

Updated: FDA Approves Leqembi Autoinjector for Maintenance Dosing in Alzheimer’s

Denise Myshko
September 16th 2025
Article

Read More

Peter Togel-stock@adobe.com

Teva Launches First Generic GLP-1 Drug for Obesity

Formulary Watch
September 16th 2025
Article

Read More

© 2025 MJH Life Sciences

All rights reserved.